as well as any new postings.
Please refer now to our website and feel free to use our 'Discussion' Page to ask any questions or speak to others with ataxia.
Thanks,
Friday, December 2, 2011
New Website
Our blog posts are now transferred to our new website.
as well as any new postings.
Please refer now to our website and feel free to use our 'Discussion' Page to ask any questions or speak to others with ataxia.
Thanks,
as well as any new postings.
Please refer now to our website and feel free to use our 'Discussion' Page to ask any questions or speak to others with ataxia.
Thanks,
Thursday, October 6, 2011
Ron Bartek - FARA
As many of you know,. Ron Bartek is the Founder and President of FARA - Friedreich's Ataxia Research Alliance. Below is an explanation/comment that he made about ViroPharma's recent affiliation with FA.
Dear friends,
Just wanted to add one additional perspective to our FA family's consideration of the recent announcement by ViroPharma and Intellect Neurosciences. We had been waiting for these press releases for some time and see the announcement as great news for several good reasons.This brings two new pharmaceutical partners into our effort to treat and cure FA.
Intellect Neurosciences has been working for quite a while to develop drugs for Alzheimer's disease and, after doing much of the preclinical work on OX1 and getting it through a phase I trial in healthy volunteers, identified FA as an excellent target for the drug.
I believe they chose FA because:
OX1 is an antioxidant and they knew FA cells suffer considerable oxidative stress;
2)OX1 seems capable of chelating iron and they knew that, in FA cells, iron accumulates in mitochondria at toxic levels and contributes to oxidative stress;
3) they saw that FA research has really matured and the FA community has become a leader among neuro-degenerative disorders in scientific research and the patient community's support of that research, and
4) they saw that the FA community has put in place the kind of infrastructure needed to support clinical drug development
.
Intellect Neurosciences has been communicating with FARA for quite some time and some of our leading FA scientists are already experimenting with OX1 so as to help give direction to subsequent development in FA.
ViroPharma is a pharmaceutical company with an excellent track record and good resources
to develop OX1 and they saw enough potential for OX1 as a treatment for FA (and other neuro-degenerative disorders subsequently) to license the drug for $6.5M up front with double-digit millions to be paid at various milestones if the drug continues to make progress. It's great to have such a capable company joining the FA family and putting their shoulder to the FA wheel.
FARA will be meeting with ViroPharma very soon. And, FARA did not have to go out looking for these two fine new pharmaceutical partners. They found FA and FARA because of all the work all of us in the FA community have done together and all the research we have supported together. We will continue to embrace new pharmaceutical partners and new potential treatment options until we have the treatments and the cure for all FA patients.
Yes, it will take a few years to develop OX1 but, in the meantime, we have more advanced potential treatment options that should be benefiting FA patients before OX1 is ready to show if it might be good enough to become part of an improved "cocktail" therapy.
You know that the very promising antioxidant A0001 should begin its final phase clinical trial in FA later this year. Who knows, if A0001 were to become an approved treatment for FA, maybe OX1 would be ready in time to be tested to see if it might be an even better antioxidant for FA. You know that the iron chelator Deferiprone has completed phase II trials in FA and the drug company, ApoPharma, is exploring prospects for a final phase trial in FA. Who knows, maybe OX1 will be later tested to see if it might have better iron-chelation properties for FA than Deferiprone.
What we do know is that we have several very promising drugs in late stages of clinical testing and several more to begin clinical testing in the very near term. We also know we will continue to bring new potential treatments into FARA's treatment pipeline and embrace promising new pharmaceutical partners until all FA patients have effective treatments and we are able to eliminate FA in subsequent generations.
Warm regards,
Ron Ronald J. Bartek
President Friedreich's Ataxia Research Alliance (FARA)
Dear friends,
Just wanted to add one additional perspective to our FA family's consideration of the recent announcement by ViroPharma and Intellect Neurosciences. We had been waiting for these press releases for some time and see the announcement as great news for several good reasons.This brings two new pharmaceutical partners into our effort to treat and cure FA.
Intellect Neurosciences has been working for quite a while to develop drugs for Alzheimer's disease and, after doing much of the preclinical work on OX1 and getting it through a phase I trial in healthy volunteers, identified FA as an excellent target for the drug.
I believe they chose FA because:
OX1 is an antioxidant and they knew FA cells suffer considerable oxidative stress;
2)OX1 seems capable of chelating iron and they knew that, in FA cells, iron accumulates in mitochondria at toxic levels and contributes to oxidative stress;
3) they saw that FA research has really matured and the FA community has become a leader among neuro-degenerative disorders in scientific research and the patient community's support of that research, and
4) they saw that the FA community has put in place the kind of infrastructure needed to support clinical drug development
.
Intellect Neurosciences has been communicating with FARA for quite some time and some of our leading FA scientists are already experimenting with OX1 so as to help give direction to subsequent development in FA.
ViroPharma is a pharmaceutical company with an excellent track record and good resources
to develop OX1 and they saw enough potential for OX1 as a treatment for FA (and other neuro-degenerative disorders subsequently) to license the drug for $6.5M up front with double-digit millions to be paid at various milestones if the drug continues to make progress. It's great to have such a capable company joining the FA family and putting their shoulder to the FA wheel.
FARA will be meeting with ViroPharma very soon. And, FARA did not have to go out looking for these two fine new pharmaceutical partners. They found FA and FARA because of all the work all of us in the FA community have done together and all the research we have supported together. We will continue to embrace new pharmaceutical partners and new potential treatment options until we have the treatments and the cure for all FA patients.
Yes, it will take a few years to develop OX1 but, in the meantime, we have more advanced potential treatment options that should be benefiting FA patients before OX1 is ready to show if it might be good enough to become part of an improved "cocktail" therapy.
You know that the very promising antioxidant A0001 should begin its final phase clinical trial in FA later this year. Who knows, if A0001 were to become an approved treatment for FA, maybe OX1 would be ready in time to be tested to see if it might be an even better antioxidant for FA. You know that the iron chelator Deferiprone has completed phase II trials in FA and the drug company, ApoPharma, is exploring prospects for a final phase trial in FA. Who knows, maybe OX1 will be later tested to see if it might have better iron-chelation properties for FA than Deferiprone.
What we do know is that we have several very promising drugs in late stages of clinical testing and several more to begin clinical testing in the very near term. We also know we will continue to bring new potential treatments into FARA's treatment pipeline and embrace promising new pharmaceutical partners until all FA patients have effective treatments and we are able to eliminate FA in subsequent generations.
Warm regards,
Ron Ronald J. Bartek
President Friedreich's Ataxia Research Alliance (FARA)
Sunday, October 2, 2011
ViroPharma pays 6.5 M. for Drug Molecule Rights - OX1
Below is a press release from ViroPharma Pharmaceuticals. It is potentially for another drug which will help in the fight to cure FA - which in my belief will have a domino effect to help other ataxia's and neurodegenerative diseases.
September 30, 2011 ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia EXTON, Pa., Sept. 30, 2011 /PRNewswire/
-- ViroPharma Incorporated (NASDAQ: VPHM) today announced the license of worldwide rights from Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.
OX1, or indole-3-propionic acid (IPA), is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease.
In a recent Phase 1 safety and tolerability study conducted in the Netherlands, OX1 was demonstrated to be safe and well tolerated at all dose levels tested. ViroPharma expects to initiate a phase 2 study within 12 to 18 months after completion of longer term toxicology studies. ViroPharma intends to file for Orphan Drug Designation upon review of the phase 2 proof of concept data.
Under the terms of the agreement,
ViroPharma has exclusive worldwide rights to develop and commercialize OX1 for the treatment, management or prevention of any disease or condition covered by Intellect's patents.
ViroPharma paid Intellect Neurosciences a $6.5 million up-front licensing fee and will pay additional milestones based upon defined events.
The maximum of these milestone payments assuming successful advancement to market could amount to $120 million. The company will also pay a tiered royalty of up to a maximum percentage of low teens, based on annual net sales.
"The mission of ViroPharma
is to improve the health of patients suffering from serious diseases and unmet medical needs, and Friedreich's Ataxia clearly fits in that class," said Vincent Milano, ViroPharma's chief executive officer.
"FA robs children and young adults of muscle coordination leading to loss of mobility, energy, speech, and hearing, and presents a significant risk of diabetes and life shortening cardiac disease.
While OX1 is early in development, this novel therapy has the potential to be a solution for this unmet need, and to make a significant difference in the lives of patients suffering from this rare disorder, and their families and caregivers."
Jennifer Farmer, MS, CGC, Executive Director, Friedreich's Ataxia Research Alliance (FARA) commented,
"We are very pleased that ViroPharma is advancing the clinical research of OX1 in Friedreich's Ataxia. Sadly, there are currently no FDA-approved treatments for this devastating disease.
We look forward to working with ViroPharma to advance this therapy forward, through building collaborative efforts with our clinical research network and connecting them to the patient community through our worldwide patient registry."
About Friedreich's Ataxia
Friedreich's Ataxia is a rare hereditary disease caused by a mutation in a gene which encodes frataxin, a protein essential for proper functioning of mitochondria, the energy pumps of the cell. In the absence of frataxin, iron in the cytoplasm builds up and causes free radical damage. The disease causes progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems; it can also lead to heart disease and diabetes. Ataxia in general refers to the inability to coordinate voluntary muscular movements. The ataxia of Friedreich's ataxia results from the degeneration of nerve tissue in the spinal cord, in particular sensory neurons essential for directing muscle movement of the arms and legs. The spinal cord becomes thinner and nerve cells lose some of their myelin sheath. The primary sites of pathology are the spinal cord and peripheral nerves. Symptoms typically begin sometime between the ages of 5 and 15 years, but may occur in patients between the ages of 20 to 30. The disease usually presents with progressive staggering or stumbling and frequent falling. The symptoms are slow and progressive with a median age of death at 35 years old. Friedreich's Ataxia is the most common form of hereditary ataxia, and is thought to affect about 1 in every 50,000 people or approximately 6,000 patients in the United States.
Currently there are no FDA approved drugs for FA.
For more information on FA, visit the Friedreich's Ataxia Research Alliance website at: www.curefa.org.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, and C. difficile infection (CDI).
Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.
ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
Disclosure Notice
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties.
Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of OX1 and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans including clinical development activities with OX1 related to Friedreich's Ataxia or other indications.
There can be no assurance that that our clinical program with OX1 will yield positive results or support further development of OX1 for Friedreich's Ataxia. The FDA or EMA may view the data regarding OX1 for Friedreich's Ataxia as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, or deny the approval of OX1 for Friedreich's Ataxia. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.
SOURCE ViroPharma Incorporated
September 30, 2011 ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia EXTON, Pa., Sept. 30, 2011 /PRNewswire/
-- ViroPharma Incorporated (NASDAQ: VPHM) today announced the license of worldwide rights from Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.
OX1, or indole-3-propionic acid (IPA), is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease.
In a recent Phase 1 safety and tolerability study conducted in the Netherlands, OX1 was demonstrated to be safe and well tolerated at all dose levels tested. ViroPharma expects to initiate a phase 2 study within 12 to 18 months after completion of longer term toxicology studies. ViroPharma intends to file for Orphan Drug Designation upon review of the phase 2 proof of concept data.
Under the terms of the agreement,
ViroPharma has exclusive worldwide rights to develop and commercialize OX1 for the treatment, management or prevention of any disease or condition covered by Intellect's patents.
ViroPharma paid Intellect Neurosciences a $6.5 million up-front licensing fee and will pay additional milestones based upon defined events.
The maximum of these milestone payments assuming successful advancement to market could amount to $120 million. The company will also pay a tiered royalty of up to a maximum percentage of low teens, based on annual net sales.
"The mission of ViroPharma
is to improve the health of patients suffering from serious diseases and unmet medical needs, and Friedreich's Ataxia clearly fits in that class," said Vincent Milano, ViroPharma's chief executive officer.
"FA robs children and young adults of muscle coordination leading to loss of mobility, energy, speech, and hearing, and presents a significant risk of diabetes and life shortening cardiac disease.
While OX1 is early in development, this novel therapy has the potential to be a solution for this unmet need, and to make a significant difference in the lives of patients suffering from this rare disorder, and their families and caregivers."
Jennifer Farmer, MS, CGC, Executive Director, Friedreich's Ataxia Research Alliance (FARA) commented,
"We are very pleased that ViroPharma is advancing the clinical research of OX1 in Friedreich's Ataxia. Sadly, there are currently no FDA-approved treatments for this devastating disease.
We look forward to working with ViroPharma to advance this therapy forward, through building collaborative efforts with our clinical research network and connecting them to the patient community through our worldwide patient registry."
About Friedreich's Ataxia
Friedreich's Ataxia is a rare hereditary disease caused by a mutation in a gene which encodes frataxin, a protein essential for proper functioning of mitochondria, the energy pumps of the cell. In the absence of frataxin, iron in the cytoplasm builds up and causes free radical damage. The disease causes progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems; it can also lead to heart disease and diabetes. Ataxia in general refers to the inability to coordinate voluntary muscular movements. The ataxia of Friedreich's ataxia results from the degeneration of nerve tissue in the spinal cord, in particular sensory neurons essential for directing muscle movement of the arms and legs. The spinal cord becomes thinner and nerve cells lose some of their myelin sheath. The primary sites of pathology are the spinal cord and peripheral nerves. Symptoms typically begin sometime between the ages of 5 and 15 years, but may occur in patients between the ages of 20 to 30. The disease usually presents with progressive staggering or stumbling and frequent falling. The symptoms are slow and progressive with a median age of death at 35 years old. Friedreich's Ataxia is the most common form of hereditary ataxia, and is thought to affect about 1 in every 50,000 people or approximately 6,000 patients in the United States.
Currently there are no FDA approved drugs for FA.
For more information on FA, visit the Friedreich's Ataxia Research Alliance website at: www.curefa.org.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options, including C1 esterase inhibitor deficiency, treatment of seizures in children and adolescents, and C. difficile infection (CDI).
Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.
ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
Disclosure Notice
Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties.
Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of OX1 and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans including clinical development activities with OX1 related to Friedreich's Ataxia or other indications.
There can be no assurance that that our clinical program with OX1 will yield positive results or support further development of OX1 for Friedreich's Ataxia. The FDA or EMA may view the data regarding OX1 for Friedreich's Ataxia as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, or deny the approval of OX1 for Friedreich's Ataxia. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.
SOURCE ViroPharma Incorporated
Friday, September 23, 2011
International Ataxia Awareness Day - IAAD
Sept. 25th is recognized around the world as International Ataxia Awareness Day (IAAD). This day is an opportunity for others around the world to gain knowledge of ataxia and become aware of those suffering from this neurodegenerative disease.
The BC Ataxia Society welcomes all forms of ataxia from people of all ages and walks of life.
Sporadic ataxia can be caused by a number of non-inherited conditions. Sporadic ataxia's include Multiple System Atrophy (MSA), Shy Drager Syndrome and Episodic Ataxia (with the exception of EA-1 and EA-2 which are often genetic.)
The hereditary ataxia's are various nervous system diseases found in the genes of individuals. Hereditary ataxia's are both recessively and dominantly inherited.
They include Friedreichs Ataxia - FA, Ataxia Telangectasia - AT (both recessive) and Spinocerebellar ataxia's -SCA's (dominant).
All share common problems of coordination of voluntary movements. These progressive diseases cause a gradual loss of physical abilities in people, often leading to the confinement of a wheelchair. These diseases are rare and currently incurable.
Today, although there is no cure, much progress has been made and medicine is ready to move at a critical stage. It is working to develop a therapy to stop the progression of the disease in the body.
The BC Ataxia Society continues to support important research being done at University Hospital in Vancouver, BC. Our donations are made possible through the efforts of individuals - ataxic, parents, friends, supporters - who give their time and energy to fight for ataxia.
On Sunday, September 25 remember those who face day to day challenges having ataxia and remember those with ataxia whom we have lost.
The BC Ataxia Society welcomes all forms of ataxia from people of all ages and walks of life.
Sporadic ataxia can be caused by a number of non-inherited conditions. Sporadic ataxia's include Multiple System Atrophy (MSA), Shy Drager Syndrome and Episodic Ataxia (with the exception of EA-1 and EA-2 which are often genetic.)
The hereditary ataxia's are various nervous system diseases found in the genes of individuals. Hereditary ataxia's are both recessively and dominantly inherited.
They include Friedreichs Ataxia - FA, Ataxia Telangectasia - AT (both recessive) and Spinocerebellar ataxia's -SCA's (dominant).
All share common problems of coordination of voluntary movements. These progressive diseases cause a gradual loss of physical abilities in people, often leading to the confinement of a wheelchair. These diseases are rare and currently incurable.
Today, although there is no cure, much progress has been made and medicine is ready to move at a critical stage. It is working to develop a therapy to stop the progression of the disease in the body.
The BC Ataxia Society continues to support important research being done at University Hospital in Vancouver, BC. Our donations are made possible through the efforts of individuals - ataxic, parents, friends, supporters - who give their time and energy to fight for ataxia.
On Sunday, September 25 remember those who face day to day challenges having ataxia and remember those with ataxia whom we have lost.
Wednesday, September 7, 2011
Welcome Back!
Wow - summer went by fast! Weather-wise it took it's time getting here but fortunately it is still continuing into September. Unfortunately though the BC Ataxia Society did not manage to get together in the summer for a picnic/bar-b-q as was hoped. It was a busy time for all of us but hopefully now with the cooler days approaching we can all get back into our routine.
We thought that our first meeting of our new term should be at a location that is central to all. So it will be held at The Caring Place in Richmond on SATURDAY OCTOBER 1ST from 1:00PM - 4:00PM.
As there were no nominations received for our Executive positions the current executive has agreed to continue for the 2011/2012 term. Swearing in will take place at our October 1st meeting.
The Executive will consist of:
President - Shannon Connors
Vice-President - Sue Billingsley
Treasurer - Kent Billingsley
More details of the meeting will be made closer to the date but in the meantime,
MARK YOUR CALENDARS.
As was discussed at our May meeting, a small fundraiser will be held in October with a larger one planned for the spring of 2012.
SUNDAY OCTOBER 16TH is the date to remember for our first fundraiser. It will be held at Legends Pub in Richmond at 1:00 PM.
Tickets cost $10.00 each and include a pasta buffet.
We plan to have 50/50 draws and hopefully some raffles and door prizes. If you know of someone willing to help with 50/50 draws or who wish to donate a raffle or door prize then please let us know at info@bcataxia.org
Tickets will be available for all members to buy/sell at the October 1st meeting. In the meantime, tell your family and friends and plan to join us for a fun afternoon.
Our new website is almost ready to go live. We have switched to a new server and are excited about our new site. Our 'Home' page will be dynamic, meaning it is constantly changing. Because of this our Blog will be set to our Homepage rather than a link and this will keep you updated on the latest news and goings on. We will have an Ataxia FAQ Page which will include a remarkable video by our own Glen Ter borg. His video has been chosen as a finalist in the BC Genescreen Competition 2011. Thank you Glenn for allowing us to share your video and Good Luck with the competition!
We will also have a 'Donate Now' button on our website which will now allow us to accept on-line donations using your credit card or Paypal thru Canada Helps. (a secure, safe donation site).
Most exciting too, our new site will include a 'Discussion' Page where you are free to ask or participate in ataxia related comments, questions or stories.
Our new site will be up and running in time for our first meeting. (Oct.1st)
STAY TUNED!
So, welcome back everyone. I hope you had a great summer and we look forward to seeing you soon!
We thought that our first meeting of our new term should be at a location that is central to all. So it will be held at The Caring Place in Richmond on SATURDAY OCTOBER 1ST from 1:00PM - 4:00PM.
As there were no nominations received for our Executive positions the current executive has agreed to continue for the 2011/2012 term. Swearing in will take place at our October 1st meeting.
The Executive will consist of:
President - Shannon Connors
Vice-President - Sue Billingsley
Treasurer - Kent Billingsley
More details of the meeting will be made closer to the date but in the meantime,
MARK YOUR CALENDARS.
As was discussed at our May meeting, a small fundraiser will be held in October with a larger one planned for the spring of 2012.
SUNDAY OCTOBER 16TH is the date to remember for our first fundraiser. It will be held at Legends Pub in Richmond at 1:00 PM.
Tickets cost $10.00 each and include a pasta buffet.
We plan to have 50/50 draws and hopefully some raffles and door prizes. If you know of someone willing to help with 50/50 draws or who wish to donate a raffle or door prize then please let us know at info@bcataxia.org
Tickets will be available for all members to buy/sell at the October 1st meeting. In the meantime, tell your family and friends and plan to join us for a fun afternoon.
Our new website is almost ready to go live. We have switched to a new server and are excited about our new site. Our 'Home' page will be dynamic, meaning it is constantly changing. Because of this our Blog will be set to our Homepage rather than a link and this will keep you updated on the latest news and goings on. We will have an Ataxia FAQ Page which will include a remarkable video by our own Glen Ter borg. His video has been chosen as a finalist in the BC Genescreen Competition 2011. Thank you Glenn for allowing us to share your video and Good Luck with the competition!
We will also have a 'Donate Now' button on our website which will now allow us to accept on-line donations using your credit card or Paypal thru Canada Helps. (a secure, safe donation site).
Most exciting too, our new site will include a 'Discussion' Page where you are free to ask or participate in ataxia related comments, questions or stories.
Our new site will be up and running in time for our first meeting. (Oct.1st)
STAY TUNED!
So, welcome back everyone. I hope you had a great summer and we look forward to seeing you soon!
Subscribe to:
Posts (Atom)